Of particular note, the fact that Notch1-ERBB3 axis functions as a universal regulatory mechanism in NSCLC, provides solid evidence and attractive possibilities for combined targeting of Notch1 and EGFR to treat EMT-driven resistance to EGFR-TKI (31). Here, EGFR is linked to non-small cell lung carcinoma.